CNS Activity and Treatment Implications

Dr. Wistuba confirms that fusion variant identification does not impact treatment selection, emphasizing that ROS1-positive versus ROS1-negative status represents the key clinical decision point. Although publications explore correlations between specific fusions and brain metastases or drug responsiveness, these have not been proven clinically relevant for treatment selection, with NGS-based testing providing the definitive diagnostic approach.

Dr. Leal explains that ROS1 fusion identification provides crucial information about disease biology, as these fusions demonstrate predilection for CNS involvement both at baseline and during disease progression. High intracranial activity from ROS1-targeted therapy has transformed treatment approaches for patients with lung cancer and brain metastases harboring ROS1 fusions. Starting patients with brain metastases on ROS1-targeted therapy can spare patients from radiation therapy toxicities, delaying radiation use for extended periods, and significantly delaying CNS recurrence or progression represents a critical endpoint for patient outcomes.

Modern agents, particularly taletrectinib, demonstrate CNS response rates exceeding 60%, providing security that oral therapy initiation can achieve meaningful responses avoiding radiation therapy. Dr. Rodriguez describes evolution in convincing radiation oncologists about the profound efficacy data, noting that responses occur rapidly with standard 6-week follow-up MRI monitoring when using oral TKIs like taletrectinib for initial treatment. Safety has been established for minimally symptomatic patients included in clinical trials, allowing TKI initiation before radiation consideration.

Dr. Rotow groups ROS1 with other actionable drivers like EGFR and ALK for very high CNS response rates, enabling systemic therapy initiation with close monitoring in most scenarios. Exceptions include large symptomatic CNS disease requiring different approaches. With PFS extending nearly 4 years with modern ROS1-directed therapies, considerations include late radiation toxicity risks like radiation necrosis, similar to ALK-positive disease where long survival necessitates careful consideration of late toxicities.

The importance of multidisciplinary discussions through tumor boards or real-time multidisciplinary clinics allows learning nuances across medical oncology and radiation oncology applications. The paradigm has shifted from crizotinib lacking sufficient CNS activity to successive agents including entrectinib, repotrectinib, and taletrectinib showing high brain responses.